Close Menu

NEW YORK – Spectrum Pharmaceuticals said on Monday after the market closed that poziotinib met its primary endpoint of objective response rate and shrunk tumors in lung cancer patients in the Phase II ZENITH20 trial.

Cohort 2 of the ZENITH20 study included 90 previously treated non-small cell lung cancer patients with HER2 exon 20 insertions. They received an oral, once daily dose of 16 mg of poziotinib, and nearly 28 percent saw their tumors shrink.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


NTRK fusions are oncogenic drivers in a variety of tumors.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.